Clinical Trials Sponsored by Luminary Therapeutics

Total 6253 results

Luminary Therapeutics
Nationwide Children

Not yet recruiting

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Luminary Therapeutics
Case Comprehensive Cancer Center

Recruiting

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin Lymphoma, B-Cell

United States
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Laminar, Inc.

Active, not recruiting

An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

Non-valvular Atrial Fibrillation

United States
Laminar Pharmaceuticals

Completed

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

Glioblastoma (GBM)

Spain
Laminar, Inc.

Active, not recruiting

Evaluating the Safety and Effectiveness of the Laminar Left Atrial Appendage Closure System

Atrial Fibrillation

Georgia, Paraguay
Laminar, Inc.

Recruiting

A Trial Evaluating the Safety and Effectiveness of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Georgia
Laminar Pharmaceuticals
Dana-Farber Cancer Institute; Hackensack Meridian Health; Laminar Pharma Inc

Recruiting

Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

High-grade Glioma | Solid Tumor, Unspecified, Child

United States
Spanish Oncology Genito-Urinary Group

Completed

Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer (MAJA)

Carcinoma, Transitional Cell

Spain
Spanish Oncology Genito-Urinary Group

Completed

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib (Spazo-2)

Metastatic Renal Cell Carcinoma

Spain
Spanish Oncology Genito-Urinary Group

Completed

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Adrenocortical Carcinoma

Spain
Spanish Oncology Genito-Urinary Group

Completed

Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy (SOGUG/0107)

Carcinoma Renal Cells

Spain
Spanish Oncology Genito-Urinary Group

Completed

Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC (SOGUG-02-06)

Carcinoma, Renal Cell

Spain
Spanish Oncology Genito-Urinary Group

Active, not recruiting

Description of the Population With Genitourinary Tumors and COVID-19 (SOGUGCOVID)

Covid19 | Genito Urinary Cancer

Spain
Spanish Oncology Genito-Urinary Group

Completed

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy (SPAZO)

Metastatic Renal Cell Carcinoma

Spain
Spanish Oncology Genito-Urinary Group

Completed

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Hormone Refractory Prostate Cancer

Spain
Spanish Oncology Genito-Urinary Group

Completed

Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent (SOGUG-07-01)

Bladder Cancer

Spain
Spanish Oncology Genito-Urinary Group

Completed

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma (SOGANG)

Metastatic Renal Cell Carcinoma

Spain
Spanish Oncology Genito-Urinary Group

Terminated

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) (PAZOPEN-SOGUG)

Penile Squamous Cell Carcinoma Stage IV

Spain
Spanish Oncology Genito-Urinary Group
GlaxoSmithKline

Completed

Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Spain
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Laminar Pharmaceuticals
Laboratory Corporation of America; Northern Institute for Cancer Research,... and other collaborators

Recruiting

LAM561 With RT and TMZ for Adults With Glioblastoma (CLINGLIO)

Glioblastoma Multiforme | Primary Glioblastoma

Spain, Italy, United Kingdom, France, Israel
Spanish Oncology Genito-Urinary Group
Pfizer

Terminated

Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques (METHEOS)

Renal Cell Carcinoma

Spain
Basque Culinary Center Fundazioa
University of Navarra

Completed

Sukalmena InAge: Nutritional-culinary Programme to Promote Adherence to a Healthy Dietary Pattern. (Sukalmena)

Obesity | Cognitive Impairment | Healthy Aging

Spain
Basque Culinary Center Fundazioa
University of Navarra

Completed

HOME COOKING: Health Empowerment Strategy in People With Type II Diabetes Mellitus (SUKALMENA)

Type 2 Diabetes Mellitus

Spain
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
Laminar, Inc.
Cardiovascular Research Foundation, New York

Enrolling by invitation

Laminar LAAX Pivotal IDE Study

Stroke | Non-valvular Atrial Fibrillation

United States
Spanish Oncology Genito-Urinary Group
AstraZeneca; MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach (IMMUNOPRESERVE)

Invasive Bladder Cancer

Spain
Spanish Oncology Genito-Urinary Group
Pivotal S.L.

Active, not recruiting

Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer (QRT-SOGUG)

Prostate Cancer Stage III | Prostate Cancer Stage IV
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
Spanish Oncology Genito-Urinary Group
Roche Pharma AG

Completed

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA)

Locally Advanced or Metastatic Urothelial Carcinoma

Spain
Spanish Oncology Genito-Urinary Group
Adknoma Health Research

Completed

SOGUG-AVELUMAB_RWD (SOGUG)

Metastatic Urothelial Carcinoma

Spain
Spanish Oncology Genito-Urinary Group
Bristol-Myers Squibb

Recruiting

Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM)

Urothelial Cancer

Spain
Spanish Oncology Genito-Urinary Group
Apices Soluciones S.L.

Completed

Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR)

Old Age; Debility | Renal Carcinoma Metastatic

Spain
CRISPR Therapeutics AG
ViaCyte

Recruiting

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Melinta Therapeutics, LLC

Recruiting

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Gram Positive Bacterial Infections

United States
TenNor Therapeutics Limited

Completed

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI)

Gram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial Infections

United States

Clinical Trials Sponsored by Luminary Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations